Traws Pharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets, December 31, 2024 and 2023
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2024 · 2023 | ||||||
| Assets · · · · · | ||||||
| Current assets: | | | | | | |
| Cash and cash equivalents | | $21,338,000 | | $20,821,000 | ||
| Tax incentive and other receivables | | 1,765,000 | | 18,000 | ||
| Prepaid expenses and other assets | | 1,848,000 | | 1,821,000 | ||
| Total current assets | | 24,951,000 | | 22,660,000 | ||
| Property and equipment, net | | 10,000 | | 22,000 | ||
| Other assets | | 1,000 | | 1,000 | ||
| Total assets | | $24,962,000 | | $22,683,000 | ||
| Liabilities and stockholders’ (deficit) equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $8,186,000 | | $5,619,000 | ||
| Accrued expenses and other liabilities | | 3,121,000 | | 3,375,000 | ||
| Deferred revenue | | 226,000 | | 226,000 | ||
| Total current liabilities | | 11,533,000 | | 9,220,000 | ||
| Deferred revenue, non-current | | 2,565,000 | | 2,791,000 | ||
| Warrant liabilities | | 42,494,000 | | — | ||
| Total liabilities | | 56,592,000 | | 12,011,000 | ||
| | | | | | | |
| Commitments and contingencies (Note 5) | | | | | | |
| | | | | | | |
| Stockholders’ (deficit) equity: | | | | | | |
| Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 7,398 shares outstanding at December 31, 2024 and no shares issued and outstanding at December 31, 2023 | | — | | — | ||
| Common stock, $0.01 par value, 250,000,000 shares authorized, 3,650,731 and 840,251 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | 36,000 | | 9,000 | ||
| Additional paid in capital | | 617,530,000 | | 493,317,000 | ||
| Accumulated deficit | | (649,154,000) | | (482,631,000) | ||
| Accumulated other comprehensive loss | | (42,000) | | (23,000) | ||
| Total stockholders’ (deficit) equity | | (31,630,000) | | 10,672,000 | ||
| Total liabilities and stockholders’ (deficit) equity | | $24,962,000 | | $22,683,000 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.